SkinBioTherapeutics Plc
SBTX.L · LSE
12/31/2024 | 6/30/2024 | 12/31/2023 | 6/30/2023 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.24 | -0.53 | 0.30 | -0.36 |
| FCF Yield | -1.95% | -8.03% | -5.12% | -8.33% |
| EV / EBITDA | -46.59 | -12.60 | -17.79 | -12.51 |
| Quality | ||||
| ROIC | -17.25% | -35.85% | -35.16% | -73.79% |
| Gross Margin | 55.65% | 52.11% | 64.01% | 10.18% |
| Cash Conversion Ratio | -1.46 | 0.78 | 0.91 | 1.02 |
| Growth | ||||
| Revenue 3-Year CAGR | 1,801,461.61% | 1,416,147.45% | 1,102,547.34% | 662,908.15% |
| Free Cash Flow Growth | 42.88% | -2.21% | 22.85% | -75.23% |
| Safety | ||||
| Net Debt / EBITDA | 0.24 | -0.01 | 2.01 | 0.75 |
| Interest Coverage | -180.11 | -38.05 | -120.76 | -397.46 |
| Efficiency | ||||
| Inventory Turnover | 0.84 | 1.12 | 0.82 | 1.48 |
| Cash Conversion Cycle | 42.12 | 60.49 | -838.03 | -270.46 |